Dulaglutide
Once-weekly GLP-1 receptor agonist (Trulicity) approved for type 2 diabetes, with modest weight loss as a secondary effect
Half-life
~5 days
Typical Dose
0.75-4.5mg weekly
Format
Injectable
Purity
Pharmaceutical grade (prescription drug)
Overview
Dulaglutide is a long-acting GLP-1 receptor agonist sold as Trulicity, and it is an FDA-approved prescription drug rather than a research vial [7]. Two GLP-1 analog chains are fused to a modified human IgG4 Fc fragment, which resists enzymatic breakdown and slows clearance enough to give a half-life near 5 days for once-weekly injection [7]. It reached HbA1c targets more often than exenatide in AWARD-1 [2], matched once-daily liraglutide for glucose control in AWARD-6 [3], and outperformed metformin as monotherapy in AWARD-3 [4]. The REWIND outcomes trial showed fewer major cardiovascular events across 9,901 patients followed for a median of 5.4 years [5], with a parallel reduction in kidney-disease progression [6]. Weight loss is real but modest: expect a few kilograms, not the double-digit percentages seen with semaglutide or tirzepatide [1,3].
Mechanism
Dulaglutide is a GLP-1 receptor agonist engineered as an Fc fusion protein, with two GLP-1 peptides linked to an IgG4 Fc backbone that resists DPP-4 degradation and renal filtration [7]. Activating the GLP-1 receptor drives glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and signals satiety through central pathways [7]. The higher 3.0mg and 4.5mg doses tested in AWARD-11 add glycemic and weight benefit over the standard 1.5mg dose, though appetite suppression stays weaker than newer incretin drugs like semaglutide and tirzepatide [1].
Researched benefits
- Once-weekly subcutaneous injection from a ready-to-use pen
- Strong HbA1c reduction of roughly 1.1-1.6% depending on dose
- Lower rate of major cardiovascular events (REWIND)
- Modest weight reduction of about 2-4.5kg
- No titration needed for glucose control at the 0.75mg starting dose
- Long-term safety record as an established approved drug
Frequently asked
Trulicity vs Ozempic?
Both are once-weekly GLP-1 receptor agonists, but they are not equal on glucose or weight. In the head-to-head SUSTAIN-7 trial, semaglutide (Ozempic) beat dulaglutide (Trulicity) on both HbA1c and weight reduction. Trulicity's edge is simplicity: the pen is ready to use and the 0.75mg starting dose needs no titration for glycemic control. If maximum weight loss is the goal, semaglutide or tirzepatide are stronger tools.
Why is Dulaglutide only injected once a week?
Its half-life sits near 5 days because two GLP-1 chains are fused to a large IgG4 Fc fragment that resists enzymatic breakdown and kidney filtration. That slow clearance is what lets a single injection cover a full week. Steady-state levels are reached after about 2 to 4 weeks of weekly dosing.
How much weight loss should I expect on Dulaglutide?
Modest. AWARD-6 recorded about 2.9kg of weight loss on the 1.5mg dose, and the higher 4.5mg dose in AWARD-11 reached roughly 4.6kg over 36 weeks. That is well short of the ~15% seen with semaglutide or ~21% with tirzepatide. Dulaglutide is a diabetes drug first, and weight loss is a secondary effect.
What are the common side effects?
The most frequent are gastrointestinal: nausea, diarrhea, vomiting, and reduced appetite, usually worst in the first few weeks and at higher doses. Dulaglutide carries a boxed warning for thyroid C-cell tumors based on rodent studies and is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Pancreatitis is a known risk.
Do I need to reconstitute or mix Dulaglutide?
No. Trulicity is a single-dose prefilled pen that injects straight from the refrigerator. There is no vial, no diluent, and no swirling or reconstitution step. You simply let it warm slightly, place the pen against the skin of the abdomen, thigh, or upper arm, and press the button.
Is Dulaglutide approved for weight loss?
No. It is approved to improve glycemic control in type 2 diabetes and to reduce cardiovascular events in adults with type 2 diabetes who have cardiovascular disease or risk factors. Any weight loss is off-label and secondary. For weight management specifically, semaglutide (Wegovy) and tirzepatide (Zepbound) hold that indication.
Scientific Literature
References
- [1]
Frias JP, et al. (2021). Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes (AWARD-11).
Diabetes Care · PubMed: 33397768
- [2]
Wysham C, et al. (2014). Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes (AWARD-1).
Diabetes Care · PubMed: 24879836
- [3]
Dungan KM, et al. (2014). Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6).
The Lancet · PubMed: 25018121
- [4]
Umpierrez G, et al. (2014). Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes (AWARD-3).
Diabetes Care · PubMed: 24842985
- [5]
Gerstein HC, et al. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND).
The Lancet · PubMed: 31189511
- [6]
Gerstein HC, et al. (2019). Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND trial.
The Lancet · PubMed: 31189509
- [7]
Glaesner W, et al. (2010). Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein.
Diabetes/Metabolism Research and Reviews · PubMed: 20503261
Citations are provided for educational purposes. Always verify primary sources before drawing research conclusions.
Ready to start your research
Get Dulaglutide from Ascension Peptides
COA-verified, US-based, discreet shipping. Use code ENHANCED for 50% off your entire order.
Buy Dulaglutide now